Hormonal
Tirzepatide, a dual GLP-1 and GIP receptor agonist, produces superior weight loss (up to 20.9%) and visceral fat reduction compared to other anti-obesity medications.
Tirzepatide is currently the most effective pharmacological tool for significant weight loss, capable of reducing body weight by over 20% in clinical trials. It works by mimicking two gut hormones (GLP-1 and GIP) to reduce appetite and fat storage. While highly effective, it requires weekly injections and careful monitoring for gastrointestinal side effects like nausea.
In the SURMOUNT-1 trial, participants without diabetes experienced a mean weight loss of up to 20.9% after 72 weeks of treatment with the highest dose of tirzepatide, compared to a mere 3.1% in the placebo group.
Why this rating
Based on a Phase 3 randomized clinical trial (SURMOUNT-1) cited in the text.
Source
The Growing Obesity Epidemic: Integrating Lifestyle, Pharmacological, and Surgical Interventions for Effective Management
Jan Siwiec et al. · Journal of Education Health and Sport · 2025
DOI 10.12775/jehs.2025.77.56962
More from this paper
- Semaglutide 2.4 mg administered weekly results in a mean weight loss of 14.9% over 68 weeks, significantly outperforming placebo.Strong
- Bariatric surgery (Roux-en-Y gastric bypass and sleeve gastrectomy) is recommended for individuals with BMI > 35 kg/m² regardless of comorbidities, and for those with BMI 30-34.9 kg/m² and metabolic diseases.Strong
- High-intensity behavioral interventions involving at least 14 sessions over six months produce significant weight loss (5-10%) and improve glycemic control.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →